Augmentation therapy for α1-antitrypsin deficiency

Drugs

Volumn 64, Issue 16, 2004, Pages 1743-1756

  Juvelekian, Georges S ^a   Stoller, James K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; RESPITIN; ZEMAIRA;

AIRWAY OBSTRUCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPNEA; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; FAMILY HISTORY; FATIGUE; FEVER; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEADACHE; HUMAN; LIVER DISEASE; LUNG EMPHYSEMA; MORTALITY; NAUSEA AND VOMITING; PROTEINASE INHIBITION; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; URTICARIA;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS;

EID: 4544235764     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464160-00002     Document Type: Review

References (47)

1. Laurell C, Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132-40
2. de Serres FJ. Worldwide racial and ethnic distribution of alphal-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122 (5): 1818-29
3. Stoller JK. Alpha-1 antitrypsin deficiency: an under-recognized but important issue for respiratory therapists. Respir Care 2003; 48 (11): 1022-4
4. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168 (7): 818-900
5. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316 (17): 1055-62
6. Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-anti-trypsin deficiency. JAMA 1988; 260 (9): 1259-64
7. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha (1)-antitrypsin, Respitin. Chest 2002; 122 (1): 66-74
8. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency: a model for conformational diseases. N Engl J Med 2002; 346 (1): 45-53
9. Gadek JE, Fells GA, Zimmerman RL, et al. Antielastases of the human alveolar structures: implications for the protease-antiprotease theory of emphysema. J Clin Invest 1981; 68 (4): 889-98
10. Breit SN, Wakefield D, Robinson JP, et al. The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin Immunol Immunopathol 1985; 35 (3): 363-80
11. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med 1988; 84 (6A): 13-31
12. Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991; 88(3): 891-7
13. Moraga F, Janciauskiene S. Activation of primary human monocytes by the oxidized form of alpha1-antitrypsin. J Biol Chem 2000; 275 (11): 7693-700
14. Churg A, Dai J, Zay K, et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest 2001; 81 (8): 1119-31
15. Brantly ML, Wittes JT, Vogelmeter CF, et al. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 1991; 100 (3): 703-8
16. Stockley RA. The pathogenesis of chronic obstructive lung diseases: implications for therapy. QJM 1995; 88 (2): 141-6
17. Stoller JK. Clinical features and natural history of severe alpha 1-antitrypsin deficiency: Roger S. Mitchell Lecture. Chest 1997; 111 (6 Suppl.): 123S-8S
18. Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 1988; 84 (6A): 52-62
19. Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68 (5): 1158-65
20. Curiel DT, Holmes MD, Okayama H, et al. Molecular basis of the liver and lung disease associated with the alpha 1-antitrypsin deficiency allele Mmalton. J Biol Chem 1989; 264 (23): 13938-45
21. Seyama K, Nukiwa T, Takabe K, et al. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)): a new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 1991; 266 (19): 12627-32
22. Seyama K, Nukiwa T, Souma S, et al. Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan. Am J Respir Crit Care Med 1995; 152 (6 Pt 1): 2119-26
23. Mahadeva R, Lomas DA. Genetics and respiratory disease: 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax 1998; 53 (6): 501-5
24. Sandford AJ, Silverman EK. Chronic obstructive pulmonary disease. 1: susceptibility factors for COPD the genotype-environment interaction. Thorax 2002; 57 (8): 736-41
25. DeMeo DL, Silverman EK. Alpha 1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59 (3): 259-64
26. Luisetti M, Seersholm N. Alpha 1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax 2004; 59 (2): 164-9
27. Ogushi F, Fells GA, Hubbard RC, et al. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80 (5): 1366-74
28. McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of Alpha 1-Antitrypsin Deficiency: Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111 (2): 394-403
29. Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society. CMAJ 1992; 146 (6): 841-4
30. Stoller JK. Augmentation therapy for severe alpha 1-antitrypsin deficiency: is the jury still out on a trial? Thorax 1998; 53(12): 1007-9
31. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha (1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160 (5 Pt 1): 1468-72
32. Barker AF, Iwata-Morgan I, Oveson L, et al. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997; 112 (3): 607-13
33. Stoller JK, Aboussouan LS. Intravenous augmentation therapy for alpha 1-antitrypsin deficiency: current understanding. Thorax. In press
34. Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT Study Group. Eur Respir J 1997; 10 (10): 2260-3
35. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin: the Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158 (1): 49-59
36. Gottlieb DJ, Luisetti M, Stone PJ, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha (1)-antitrypsin deficiency: the American-Italian AATD Study Group. Am J Respir Crit Care Med 2000; 162 (6): 2069-72
37. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118 (5): 1480-5
38. Wencker M, Fuhrmann B, Banik N, et al. Longitudinal follow-up of patients with alpha (1)-protease inhibitor deficiency before and during therapy with IV alpha (1)-pcotease inhibitor. Chest 2001; 119 (3): 737-44
39. Stockley RA, Bayley DL, Unsal I, et al. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002; 165 (11): 1494-8
40. Abboud RT, Ford GT, Chapman KR. Alpha1-antitcypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J 2001; 8(2): 81-8
41. Wencker M, Banik M, Buhl R, et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11 (2): 428-33
42. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003; 123 (5): 1425-34
43. Gildea TR, Shermock KM, Singer ME, et al. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 167 (10): 1387-92
44. Hay JW, Robin ED. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 1991; 81 (4): 427-33
45. Allans SA, O'Malley P. Should health-care systems pay for replacement therapy in patients with alpha (1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 2000; 117 (3): 875-80
46. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204 (5): 345-51
47. Sandhaus RA. New and emerging therapies for alpha 1-antitrypsin deficiency. Thorax. In press